此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

优特克单抗在患有中度至重度活动性克罗恩病的儿科参与者中的研究 (UNITI Jr)

2026年7月2日 更新者:Janssen Research & Development, LLC

优特克单抗作为开放标签静脉内诱导治疗的疗效、安全性和药代动力学的 3 期研究,随后在患有中度至重度活动性克罗恩病的儿科参与者中进行随机双盲皮下优特克单抗维持治疗

本研究的目的是评估优特克单抗剂量在诱导临床缓解(全球)和维持临床缓解(美国)方面的疗效;评估患有中度至重度活动性克罗恩病的儿科参与者的安全性和优特克单抗暴露(药代动力学 [PK])。

研究概览

研究类型

介入性

注册 (实际的)

101

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Be’er Ya‘aqov、以色列、70300
        • Yitzhak Shamir Medical Center
      • Haifa、以色列、34362
        • Carmel Medical Center
      • Jerusalem、以色列、9103102
        • Shaare Zedek Medical Center
      • Petah Tikva、以色列、4920235
        • Schneider Children's Medical Center
      • Kazan'、俄罗斯、420138
        • Kazan State Medical University
      • Moscow、俄罗斯、119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod、俄罗斯、603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl、俄罗斯、150032
        • Yaroslavl Regional Children's Clinical Hospital
      • Budapest、匈牙利、1083
        • Semmelweis Egyetem
      • Debrecen、匈牙利、4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc、匈牙利、3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza、匈牙利、4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged、匈牙利、6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
      • Aachen、德国、52074
        • Universitätsklinikum Aachen
      • Berlin、德国、13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen、德国、45147
        • Universitätsklinikum Essen
      • Hanover、德国、30625
        • Medizinische Hochschule Hannover
      • Munich、德国、80337
        • Dr. von Haunersches Kinderspital
      • Regensburg、德国、93049
        • KUNO Klinik St. Hedwig
      • Ulm、德国、89075
        • Universitätsklinikum Ulm
      • Bunkyō City、日本、113 8431
        • Juntendo University Hospital
      • Gunma、日本、371-0034
        • Gunma University Hospital
      • Ikoma、日本、630-0293
        • Kindai University Nara Hospital
      • Kurume、日本、830-0011
        • Kurume University Hospital
      • Saitama Shi、日本、330-8777
        • Saitama Childrens Medical Center
      • Sendai、日本、989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku、日本、157 8535
        • National Center for Child Health and Development
      • Shimotsuke、日本、329-0498
        • Jichi Medical University Hospital
      • Tsu、日本、514 8507
        • Mie University Hospital
      • Brussels、比利时、1200
        • Cliniques Universitaires Saint Luc
      • Brussels、比利时、1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent、比利时、9000
        • UZ Gent
      • Jette、比利时、1090
        • UZ Brussel
      • Leuven、比利时、3000
        • UZ Leuven
      • Gdansk、波兰、80 803
        • Szpital im. M. Kopernika
      • Krakow、波兰、30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów、波兰、35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw、波兰、04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw、波兰、04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
    • Delaware
      • Wilmington、Delaware、美国、19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta、Georgia、美国、30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic
    • New Jersey
      • Morristown、New Jersey、美国、07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte、North Carolina、美国、28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland、Ohio、美国、44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey、Pennsylvania、美国、17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth、Texas、美国、76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Pediatric Specialists Of Virginia
      • Birmingham、英国、B4 6NH
        • Birmingham Children's Hospital
      • Bristol、英国、BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge、英国、CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh、英国、EH16 4TJ
        • Royal Hospital for Children and Young People
      • London、英国、E1 2AT
        • Royal London Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 17年 (孩子)

接受健康志愿者

不

描述

纳入标准:

  • 患有克罗恩病或伴有活动性结肠炎、回肠炎或回肠结肠炎的瘘管型克罗恩病,过去任何时间通过内窥镜检查和组织学证实
  • 必须患有中度至重度活动性克罗恩病(由基线小儿克罗恩病活动指数 [PCDAI] 得分大于 [>] 30 定义);进行回肠结肠镜检查,活动性克罗恩病的证据定义为在本研究的筛选期间存在溃疡(等于克罗恩病 [SES-CD] 的简单内镜评分 [SES-CD] 评分大于或等于 [>=] 3)。 回肠结肠镜检查程序必须在第 0 周(诱导期)进行研究干预之前的大约 3 周内进行。 在第 0 周(诱导期)访视前 3 个月内记录的视频回肠结肠镜检查可用于对接受过回肠结肠镜检查但因其他原因未通过初步筛查的参与者进行重新筛查,具体情况视具体情况而定,之后与发起人协商。 如果由于狭窄或肠道准备不充分而无法评估溃疡,则至少可以应用以下标准之一: C 反应蛋白 (CRP) 异常(> 0.3 毫克每分升 [mg/dL] 或 3.0 毫克每升[mg/L] 筛选时)或;筛选时 >= 250 毫克每公斤 [mg/kg] 或 >= 250 微克每克 [mcg/g] 的粪便钙卫蛋白
  • 如果接受肠内营养,则必须在诱导第 0 周(第 I-0 周)之前至少 2 周保持稳定的方案
  • 具有生育潜力的女性在筛选时和研究干预实施前的第 I-0 周必须具有阴性的高度敏感的尿妊娠试验

排除标准:

  • 有克罗恩病的并发症,如症状性狭窄或狭窄、短肠综合征或任何其他可能需要手术的表现,这可能会妨碍使用 PCDAI 评估对治疗的反应,或者可能会混淆评估优特克单抗治疗的效果
  • 有潜伏性或活动性肉芽肿感染、组织胞浆菌病或球孢子菌病病史,或在筛查前有非结核分枝杆菌感染
  • 任何恶性肿瘤的存在或病史,包括淋巴增生性疾病(包括淋巴瘤)的存在或病史,或提示可能存在淋巴增生性疾病的体征和症状,例如异常大小或位置的淋巴结肿大(例如,颈部后三角、锁骨下、滑车上、或主动脉周围区域),以及意义未明的单克隆丙种球蛋白病,或有临床意义的肝肿大或脾肿大
  • 有中度或重度进行性或不受控制的肝或肾功能不全病史;或显着的心脏、血管、肺、胃肠道、内分泌、神经、血液、精神(包括自杀倾向)或代谢紊乱
  • 在计划的第一剂研究干预之前的 3 个月内接受过包括任何研究性疫苗在内的研究性干预或使用过侵入性研究性医疗设备,或者目前正在参加一项研究;接受 2019 年冠状病毒病 (COVID-19) 研究疫苗不是自动排除标准

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:开放标签 Ustekinumab 静脉注射 (IV):诱导期
根据体表面积 (BSA)(毫克每平方米 [mg/m^2])或体重分级诱导剂量(毫克每千克),所有参与者将在第 0 周 (I-0) 接受单次 ustekinumab IV 给药[毫克/公斤])。
Ustekinumab 将在诱导期静脉内给药,在维持期皮下给药。
实验性的:Ustekinumab 皮下注射 (SC) 每 8 周一次 (q8w):维持期
参与者将在维持周(M 周)-0、M-8、M-16、M-24 接受基于 BSA(mg/m^2)或体重分级诱导剂量(mg/kg)的 ustekinumab q8w SC 给药、M 32 和 M-40 以及匹配的安慰剂在 M-12 和 M-36 周保持盲态。
Ustekinumab 将在诱导期静脉内给药,在维持期皮下给药。
匹配的安慰剂将作为 SC 注射给药。
实验性的:Ustekinumab SC 每 12 周一次 (q12w):维持期
参与者将在第 M-0、M-12、M-24、M-36 周接受基于 BSA (mg/m^2) 或体重分级诱导剂量 (mg/kg) 的优特克单抗 q12w SC 给药,并在第 M-8、M-16、M-32 和 M-40 周保持盲目。
Ustekinumab 将在诱导期静脉内给药,在维持期皮下给药。
匹配的安慰剂将作为 SC 注射给药。

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
大体时间:Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
大体时间:Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
大体时间:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
大体时间:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
大体时间:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
大体时间:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
大体时间:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
大体时间:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
大体时间:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
大体时间:Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

次要结果测量

结果测量
措施说明
大体时间
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
大体时间:Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
大体时间:Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
大体时间:Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
大体时间:Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
大体时间:Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
大体时间:Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
大体时间:Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
大体时间:Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
大体时间:Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年4月6日

初级完成 (实际的)

2024年11月28日

研究完成 (实际的)

2025年3月3日

研究注册日期

首次提交

2020年12月14日

首先提交符合 QC 标准的

2020年12月14日

首次发布 (实际的)

2020年12月17日

研究记录更新

最后更新发布 (实际的)

2026年7月30日

上次提交的符合 QC 标准的更新

2026年7月2日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • CR108864
  • 2019-004225-24 (EudraCT编号)
  • CNTO1275CRD3004 (其他标识符:Janssen Research & Development, LLC)
  • 2023-504978-38-00 (注册表标识符:EUCT number)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

强生旗下杨森制药公司的数据共享政策可在 www.janssen.com/clinical-trials/transparency 获取。 如本网站所述,访问研究数据的请求可以通过耶鲁大学开放数据访问 (YODA) 项目网站 yoda.yale.edu 提交

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅